# US 2017/0285037 A1 · Scoring methods for anti-pd therapy eligibility and compositions for performing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285037 A1
- Document ID: US20170285037A1
- Status: Published application
- Kind: A1
- Application number: 15/422,350
- Filed: 2017-02-01
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: Agilent Technologies, Inc.; Merck Sharp & Dohme Corp.
- Applicants: Agilent Technologies, Inc.
- Inventors: Karina Kulangara; Nancy Zhang; David Stanforth; Greg Angelides; Stephanie Waldroup
- Web page: https://patentgrep.com/patent/US20170285037A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 2333/70532: B7 molecules, e.g. CD80, CD86
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

## Claims

### Claim 1

A method for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent, the method comprising:
determining the number of viable PD-L1 positive tumor cells, the number of viable PD-L1 negative tumor cells, and the number of viable PD-L1 positive mononuclear inflammatory cells (MIC) in a tumor tissue sample from a subject having a malignancy;
calculating a combined positive score (CPS) for the tumor tissue sample using the formula:
C


P


S
=
PD

-

L

1


positive


tumor


cells
+
PD

-

L

1


positive


MIC
PD

-

L

1


positive


tumor


cells
+
PD

-

L

1


negative


tumor


cells
×
100

%
wherein the subject is eligible for treatment with an anti-PD therapeutic agent when the CPS is above a threshold.

### Claim 2 (depends on 1)

The method of claim 1, wherein the threshold is from about 10% to about 1%.

### Claim 3 (depends on 1)

The method of claim 1, wherein the threshold is 1%.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tumor tissue sample is a tissue section of a tumor biopsy.

### Claim 5 (depends on 4)

The method of claim 4, wherein PD-L1 is detected by immunohistochemistry (IHC) staining.

### Claim 6 (depends on 4)

The method of claim 4, wherein the tumor tissue section is a formalin fixed and embedded in paraffin wax (FFPE) tumor tissue section.

### Claim 7 (depends on 4)

The method of claim 4, wherein the tissue section is stained.

### Claim 8 (depends on 7)

The method of claim 7, wherein the stain is a hematoxylin and eosin (H&E) stain.

### Claim 9 (depends on 4)

The method of claim 4, wherein the viable PD-L1 positive tumor cells, the number of viable PD-L1 negative tumor cells, and the number of viable PD-L1 positive MIC are counted in the tumor nests and the adjacent supporting stroma of the tumor tissue sample.

### Claim 10 (depends on 1)

The method of claim 1, wherein the tumor tissue sample is a cell suspension.

### Claim 11 (depends on 10)

The method of claim 10, wherein the number of viable PD-L1 positive tumor cells, the number of viable PD-L1 negative tumor cells, and the number of viable PD-L1 positive MIC in the tumor tissue sample are determining by flow cytometry.

### Claim 12 (depends on 1)

The method of claim 1, wherein one or more additional marker is detected in the tumor tissue sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the marker is specific for MIC or is selected from the group consisting of: CD3, CD5, CD4, CD7, CD8, and CD20.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method further comprises, prior to the determining step, contacting the tumor tissue sample with a anti-PD-L1 antibody or binding fragment thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the number of viable PD-L1 positive tumor cells, the number of viable PD-L1 negative tumor cells, and the number of viable PD-L1 positive MIC in the tumor tissue sample are determined by single cell sequencing.

### Claim 16 (depends on 1)

The method of claim 1, wherein the malignancy is selected from the group consisting of: gastric cancer, head and neck cancer, renal cell carcinoma, urothelial/bladder carcinoma, ovarian carcinoma, myeloma, melanoma, lung cancer, squamous cell carcinoma, classical Hodgkin's lymphoma, and breast cancer (e.g., triple negative breast cancer, hormone receptor positive (ER and/or PR) and Her2 positive breast cancer), small cell lung cancer, salivary gland carcinoma, vulvar carcinoma, thyroid carcinoma, anal canal carcinoma, biliary carcinoma, mesothelioma, cervical carcinoma, and neuroendocrine carcinoma.

### Claim 17 (depends on 1)

The method of claim 1, wherein the anti-PD therapeutic agent inhibits the anti-cell death activity of PD-1/PD-L1.

### Claim 18 (depends on 1)

The method of claim 1, wherein the anti-PD therapeutic agent comprises an anti-PD or anti-PD-L1 specific antibody or binding fragment thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the anti-PD therapeutic agent is selected from the group consisting of: Avelumab (MSB0010178C), Nivolumab, Pembrolizumab, BMS-936559, MPDL3280A, Pidilizumab, and MEDI4736.

### Claim 20

A kit for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent, comprising:
a detectable PD-L1 specific binding agent; and
instructions for calculating a combined positive score (CPS).
